United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/697,036	10/31/2003	Hiroki Nakajima	Q78242	8374	
23373 SLICHDLIE MI	23373 7590 01/22/2008 SUGHRUE MION, PLLC		EXAMINER		
2100 PENNSYLVANIA AVENUE, N.W.			MONSHIPOU	MONSHIPOURI, MARYAM	
SUITE 800 WASHINGTON, DC 20037			ART UNIT	PAPER NUMBER	
			1656		
		•	· ·		
			MAIL DATE	DELIVERY MODE	
			01/22/2008	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)				
•	10/697,036	NAKAJIMA, HIROKI				
Office Action Summary	Examiner	Art Unit				
	Maryam Monshipouri	1656				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
1) Responsive to communication(s) filed on <u>RCE request of 1/9/08</u> .						
,						
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4)⊠ Claim(s) <u>1,2 and 5-14</u> is/are pending in the application.						
4a) Of the above claim(s) <u>14</u> is/are withdrawn from consideration.						
5)⊠ Claim(s) <u>1,2 and 5-10</u> is/are allowed.						
6)⊠ Claim(s) <u>11 and 13</u> is/are rejected.						
7)⊠ Claim(s) <u>12</u> is/are objected to.						
8) Claim(s) are subject to restriction and/or election requirement.						
Application Papers						
9) The specification is objected to by the Examiner.						
10) The drawing(s) filed on is/are: a) □ accepted or b) □ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
12)⊠ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a)⊠ All b)□ Some * c)□ None of:						
1.⊠ Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.						
		•				
Attachment(s)						
 Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) 	4) Interview Summary Paper No(s)/Mail Da					
3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	5) Notice of Informal P					

Art Unit: 1656

A request for continued examination (RCE) under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 1/9/08 has been entered.

In view of applicant's amendment of 1/9/08, elected claims 1-2, 5-10 are now in condition for allowance. Withdrawn claims 11-13 are hereby rejoined with the elected invention (see MPEP section 821.04) under provisions of re Ochiai. Claim 14 remains withdrawn as drawn to non-elected invention. Claims 3-4, 15-22 are canceled.

On 1/11/08, 1/14/08, 1/15/08 the examiner called Mr. John D. Callahan and negotiated allowance but Mr. Callahan neither gave the examiner authority to cancel non-elected claims not responded positively to the examiner's proposals.

DETAILED ACTION

Claims 1-2, 5-10, 11-13 are under examination on the merits.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 11 and 13 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. The phrase "amount of intracellular signal transduction" in claim 11 (and its dependent claim13) is unclear. Applicant has not

Art Unit: 1656

defined said phrase specifically in the specification. According to prior art, said phrase is generic and non-specific because it refers to numerous events within a cell, such as neurite outgrowth, cell attachment, cell morphology change, cell growth etc. It in unclear which specific "signal transduction amount" is measured. Appropriate clarification is required.

Claim 13 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. The phrase "searching an antifungal compound" in preamble of claim 13 is confusing. Firstly it is grammatically incomplete because the term "searching" must be followed by the term "for". Secondly, according to the examiner's understanding, in claim 12 one starts with a series of test compounds with potential antifungal activity and after steps 1-3, will identify the potent antifungal compounds. Therefore, in claim 13, one is selecting a "potent" antifungal compound. However, claim 13 as written fails to distinctly claim the invention. Applicant is advised to substitute said phrase with "screening for potent antifungal compounds" or an equivalent phrase in response to this office action, based on the support provided in the specification.

Allowable Subject Matter

Claim 12 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. This is because a method of assaying for antifungal compounds utilizing an amount of growth of a transformed budding yeast

Application/Control Number: 10/697,036

Art Unit: 1656

according to claim 1 is novel and non-obvious because it is directed to a method of use of a product which is both novel and non-obvious.

Claims 1-2, 5-10 are allowed for the reasons of record.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Maryam Monshipouri whose telephone number is (571) 272-0932. The examiner can normally be reached on Tues.-Fri., from 7:00 a.m to 5:30 p.m..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Kathleene Kerr Bragdon can be reached on (571) 272-0931. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Maryam Monshipouri Ph.D. Primary Examiner

**: